Abstract
A sandwich enzyme immunoassay (EIA) was established by using purified β 2-microglobulin ( β 2-MG) as a standard protein and a polyclonal antibody raised against human β 2-MG. The EIA was applied for the measurement of β 2-MG levels in human cerebrospinal fluid (CSF) from parkinsonian patients and control patients devoid of neurological diseases. β 2-MG contents in CSF of the control group and the parkinsonian group were 1.81 ± 0.11 μg/ml CSF and 0.63 ± 0.09 μg/ml CSF, respectively. Thus, β 2-MG content in CSF was reduced in parkinsonian patients to less than 35% of the control value ( P < 0.005). We had previously reported that the activity and content of dopamine β-hydroxylase (DBH) were decreased in CSF from parkinsonian patients. A significant positive correlation ( r = 0.87) was observed between the β 2-MG content and DBH activity for CSF from 45 patients. These results suggest a probable link between an immunological change and the changes in catecholaminergic neurons in Parkinson's disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
